The sphericity of erythrocytes and its communication with biochemical, hemostasis and rheological by properties of blood at the patients with coronary disease and arterial hypertension

The aim of the work was to study the peculiarities of the influence of bloodfactors on the development of spherocytosis in patients with coronary disease and arterial hypertension. The study involved 30 patients with coronary disease and 24 patients arterial hypertension with the study of their clinical status and biochemical parameters of blood, hemostasis, blood cell analysis. It was found that the increase in the pool spherocytic cells in patients with arterial hypertension were associated with increased nitric oxide production, while in patients with coronary disease spherocytosis was due to an increase in the concentration of reactive oxygen metabolites

PROTEINS OF THE ERYTHROCYTE MEMBRANE AND METABOLIC SYNDROME

There is no literature data on the changes of structural and functional qualities of the erythrocyte membrane at the arterial hypertension (AH) complicated and non-complicated by the metabolic syndrome (MS). Although the changes of interrelation between the proteins of erythrocyte membrane at the AH can influence the deformability of the membrane itself. The aim of the work was to estimate the peculiarities of interrelation between the proteins of erythrocyte membrane in the patients with arterial hypertension complicated and non-complicated by the metabolic syndrome. The research included 51 men with AH and 29 clinically healthy men which were divided into 3 groups: group 1 - control; group 2 - men with AH complicated with MS (n = 29); group 3 - men with AH non-complicated with MS (n = 22). We studied blood lipids, biochemical and hemostasiological parameters, assessed 10 proteins of erythrocyte membrane. Patients of the 2nd and 3rd groups had different content of α- and β-spectrins, anion-transport protein (ATP), plates 4.1, glycerol-3-phosphatededehydrogenase (G-3-PDG), glutathione S-transferase (GST). The results of the research showed that metabolic syndrome at the AH can not only influence the state of vessel wall but also cause significant disorders of structural and functional qualities of the erythrocyte membrane

Level of membrane-bound hemoglobin and red-cell membrane proteins in patients with essential hypertension complicated and not complicated with metabolic syndrome

We studied the effect of different levels of membrane-bound hemoglobin on the level of red-cell membrane proteins and also their interrelation in patients with essential hypertension with and without metabolic syndrome. It wasfound that high membrane-bound hemoglobin is closely related to the low level of high-density lipoproteins and high level of low-density lipoproteins in patients with essential hypertension complicated with metabolic syndrome. In patients with essential hypertension not complicated with metabolic syndrome high membrane-bound hemoglobin is related to the increased prothrombin time and decreased blood urea nitrogen. In patients with essential hypertension complicated with metabolic syndrome high membrane-bound hemoglobin significantly influences the level of membrane contractile proteins (actin, tropomiosine). In patients with essential hypertension without metabolic syndrome high membrane-bound hemoglobin is accompanied by the decrease of structural and integral membrane proteins levels (anion-transport protein and protein 4.1). As the result of quantitative changes in these proteins and change in their interrelations in patients with ssential hypertension complicated with metabolic syndrome more intensive disorders of structural and functional organization of red-cell membrane can appear

Hygienic assessment of microclimate parameters of the department of hygiene and occupational diseases of USMU

The purpose of the study is to measure the parameters of the microclimate at the Department of Hygiene and Occupational Diseases of USMU and determine their compliance with the norms of SanPiN 1.2.3685-21.Цель исследования – измерить параметры микроклимата на кафедре гигиены и профессиональных болезней УГМУ и определить их соответствие нормам СанПиН 1.2.3685-21

Commitment of Yekaterinburg residents to wearing face masks during the Covid-19 pandemic

The aim of the study - to assess commitment of Yekaterinburg residents to wearing face coverings in crowded and/or enclosed places and to prepare recommendations in the form of a booklet to promote itЦель исследования - оценить соблюдение жителями города Екатеринбург масочного режима в местах массового скопления людей и разработать рекомендации в виде буклета для привлечения населения к его соблюдени

The role of the p90 ribosomal S6 kinase family in prostate cancer progression and therapy resistance.

Prostate cancer (PCa) is the second most commonly occurring cancer in men, with over a million new cases every year worldwide. Tumor growth and disease progression is mainly dependent on the Androgen Receptor (AR), a ligand dependent transcription factor. Standard PCa therapeutic treatments include androgen-deprivation therapy and AR signaling inhibitors. Despite being successful in controlling the disease in the majority of men, the high frequency of disease progression to aggressive and therapy resistant stages (termed castrate resistant prostate cancer) has led to the search for new therapeutic targets. The p90 ribosomal S6 kinase (RSK1-4) family is a group of highly conserved Ser/Thr kinases that holds promise as a novel target. RSKs are effector kinases that lay downstream of the Ras/Raf/MEK/ERK signaling pathway, and aberrant activation or expression of RSKs has been reported in several malignancies, including PCa. Despite their structural similarities, RSK isoforms have been shown to perform nonredundant functions and target a wide range of substrates involved in regulation of transcription and translation. In this article we review the roles of the RSKs in proliferation and motility, cell cycle control and therapy resistance in PCa, highlighting the possible interplay between RSKs and AR in mediating disease progression. In addition, we summarize the current advances in RSK inhibitor development and discuss their potential clinical benefits